Julia K. Gittler

https://assets.montefioreeinstein.org/profiles/images/physphoto/Gittler_Julia_MD_420x504.jpg

First Name

Julia

Last Name

Gittler

NPI

1427492081

Faculty ID

16099

CMO Specialties

Clinical Terms

Employment Status

part-time

Patient Type

Pediatric

Department

Gender

Female

Email

Phone

Titles

Locations

Education and Trainings

Professional Interests

<p class="MsoNormal" style="mso-pagination: widow-orphan;">Julia K. Gittler, MD, is an attending physician and Assistant Professor at Montefiore-Einstein. Dr. Gittler&rsquo;s clinical areas of focus include all areas of pediatric dermatology, including eczema, vascular and other birthmarks, acne, genetic skin disorders and other pediatric dermatologic conditions.</p>
<p class="MsoNormal">Dr. Gittler earned her Bachelor of Arts at the University of Pennsylvania College of Arts and Sciences in 2008 and graduated summa cum laude. From 2008 to 2013, she attended the Albert Einstein College of Medicine, receiving her Doctor of Medicine and earning distinction in dermatology research through a research fellowship at the Rockefeller University. Her training also includes completion of a yearlong pediatrics internship at Cohen Children&rsquo;s Medical Center in 2014, a three-year dermatology residency at New York University in 2017 and a yearlong pediatric dermatology fellowship at Columbia University in 2018.</p>
<p class="MsoNormal" style="mso-pagination: widow-orphan;">Following her clinical interests, Dr. Gittler&rsquo;s research focus is on pediatric dermatology. Her work has been published in many peer-reviewed journals. She has also shared her research through poster presentations and lectures at regional and national conferences.</p>
<p class="MsoNormal" style="mso-pagination: widow-orphan;">Dr. Gittler is certified in pediatric dermatology by the American Board of Dermatology. She is a member of the American Academy of Dermatology and the Society of Pediatric Dermatology.</p>

Research Areas

Research Profile

Clinical Profile

CHAM Provider

Off

Professional Title

Elsevier Profile

EMR ID

102886

Is Open Scheduling

On

Benedict C. Wu

https://documentapi-fargate-documentbucket-15qi4tpdvnhlz.s3.amazonaws.com/218/41dd1920-3372-11ec-868d-89cf3c4ab01c.jpg

First Name

Benedict

Last Name

Wu

NPI

1730538596

Faculty ID

17053

CMO Specialties

Clinical Terms

Employment Status

Full Time

Patient Type

Adult

Department

Gender

Male

Email

Phone

Titles

Locations

Education and Trainings

Professional Interests

<p>Benedict (Benny) Wu, DO, PhD, is the Director of Inpatient Dermatology and Assistant Professor at Montefiore-Einstein. Dr. Wu&rsquo;s clinical interests extend to inpatient and complex medical dermatology areas, including connective tissue disorders, autoimmune bullous disorders, immunodermatology, cutaneous presentation of systemic conditions, and cutaneous lymphomas.</p>
<p>After earning his Bachelor of Science in biological sciences from the University of California, Irvine, Dr. Wu attended the University of Medicine and Dentistry of New Jersey, earning his Master of Biomedical Sciences. He later attended Rowan University, earning his Doctor of Philosophy in Cell and Molecular Biology in 2014 and his Doctor of Osteopathic Medicine in 2016. His postdoctoral training began with an internship in internal medicine at Drexel University College of Medicine, followed by a clinical research fellowship at Northwestern University. In 2021, he completed his Dermatology residency at Broward Health in Fort Lauderdale, Florida.</p>

Research Areas

Research Profile

Clinical Profile

CHAM Provider

Off

Professional Title

Clinical Focus

<span style="color:#525458;font-family:Arial, Helvetica, sans-serif;background-color:#ffffff;">&nbsp;Dr. Wu&rsquo;s clinical interests extend to inpatient and complex medical dermatology areas, including connective tissue disorders, autoimmune bullous disorders, immunodermatology, cutaneous presentation of systemic conditions, and cutaneous lymphomas.</span>

Research Focus

<span style="color:#525458;font-family:Arial, Helvetica, sans-serif;background-color:#ffffff;">Dr. Wu&rsquo;s research investigates several questions. His research focus spans from his work in the clinic to the basic sciences. For example, does physical and/or emotional stress significantly exacerbate complex medical dermatoses? In the future, he hopes to examine neutrophil dysfunction at the cellular and molecular level from tissue and blood samples from neutrophil-predominant dermatoses.</span>

Elsevier Profile

Selected Publications

<p><span style="font-size: 11pt; font-family: 'Century Gothic', sans-serif; color: #212121;">Hopkins ZH, Wu BC, Nousari CH. Rituximab versus Mycophenolate Mofetil in Pemphigus Vulgaris.&nbsp;</span><em><span style="font-size: 11pt; font-family: 'Century Gothic', sans-serif; color: #212121;">N Engl J Med</span></em><span style="font-size: 11pt; font-family: 'Century Gothic', sans-serif; color: #212121;">. 2021;385(11):1055-1056. doi:10.1056/NEJMc2111763</span></p>
<p><span style="font-size: 11pt; font-family: 'Century Gothic', sans-serif; color: #212121;">Nousari Y, Wu BC, Tausk F. From the Caravels to the Wards: Scurvy and Schizophrenia [published online ahead of print, 2021 Jun 8].&nbsp;<em>J Acad Consult Liaison Psychiatry</em>. 2021;S2667-2960(21)00097-5. doi:10.1016/j.jaclp.2021.05.006</span></p>
<p><span style="font-size: 11pt; font-family: 'Century Gothic', sans-serif;">Nousari Y, Wu BC, Valenzuela G. Successful use of baricitinib in the treatment of refractory rheumatoid arthritis-associated Sweet syndrome [published online ahead of print, 2021 Apr 29].&nbsp;<span class="em" style="border: none; vertical-align: baseline;"><em><span style="border: none;"><span style="border: none;">Clin Exp Dermatol</span></span></em></span>. 2021;10.1111/ced.14712. doi:10.1111/ced.14712</span></p>
<p><span style="font-size: 11pt; font-family: 'Century Gothic', sans-serif;">Erickson, T. R., Murphrey, M. B., Abu-Zayed, H., Wu, B., Ibler, E., Rangel, S. M., &amp; Paller, A. S. (2020). Transepidermal water loss in the orphan forms of ichthyosis.&nbsp;<span class="em" style="border: none; vertical-align: baseline;"><em><span style="border: none;"><span style="border: none;">Pediatric dermatology</span></span></em></span>,&nbsp;<span class="em" style="border: none; vertical-align: baseline;"><em><span style="border: none;"><span style="border: none;">37</span></span></em></span>(4), 771&ndash;773. https://doi.org/10.1111/pde.14221</span></p&gt;

EMR ID

159114

Biography

<p style="padding-top:0px;color:#525458;font-family:Arial, Helvetica, sans-serif;background-color:#ffffff;">Benedict (Benny) Wu, DO, PhD, is the Director of Inpatient Dermatology and Assistant Professor at Montefiore-Einstein. Dr. Wu&rsquo;s clinical interests extend to inpatient and complex medical dermatology areas, including connective tissue disorders, autoimmune bullous disorders, immunodermatology, cutaneous presentation of systemic conditions, and cutaneous lymphomas.</p><p style="padding-top:0px;color:#525458;font-family:Arial, Helvetica, sans-serif;background-color:#ffffff;">After earning his Bachelor of Science in biological sciences from the University of California, Irvine, in 2006, Dr. Wu attended the University of Medicine and Dentistry of New Jersey, earning his Master of Biomedical Sciences in 2007. He later attended Rowan University, earning his Doctor of Philosophy in Cell and Molecular Biology in 2014 and his Doctor of Osteopathic Medicine in 2016. His postdoctoral training began with an internship in internal medicine at Drexel University College of Medicine in 2017, followed by a clinical research fellowship at Northwestern University in 2018. In 2021, he completed a three-year dermatology residency at Broward Health.</p><p style="padding-top:0px;color:#525458;font-family:Arial, Helvetica, sans-serif;background-color:#ffffff;">Dr. Wu&rsquo;s research investigates several questions. His research focus spans from his work in the clinic to the basic sciences. For example, does physical and/or emotional stress significantly exacerbate complex medical dermatoses? In the future, he hopes to examine neutrophil dysfunction at the cellular and molecular level from tissue and blood samples from neutrophil-predominant dermatoses. He has shared his research in many oral and poster presentations, as well as in peer-reviewed publications.</p><p style="padding-top:0px;color:#525458;font-family:Arial, Helvetica, sans-serif;background-color:#ffffff;">Dr. Wu is a member of several professional societies, including the American Academy of Dermatology, the Medical Dermatology Society, the Society for Dermatological Hospitalists, and the Society for Investigative Dermatology.</p>

Is Open Scheduling

On

Marc Vimolratana

https://documentapi-fargate-documentbucket-15qi4tpdvnhlz.s3.amazonaws.com/218/58a00310-6a8c-11ec-afc2-e529147b8d1e.jpg

First Name

Marc

Last Name

Vimolratana

NPI

1467870683

Faculty ID

17157

CMO Specialties

Clinical Terms

Employment Status

Full Time

Patient Type

Adult

Department

Gender

Male

Email

Phone

Titles

Locations

Education and Trainings

Research Profile

Clinical Profile

CHAM Provider

Off

Professional Title

Clinical Focus

Dr. Vimolratana is a general thoracic surgeon with a clinical focus on thoracic surgical oncology, including minimally invasive surgery for lung and esophageal cancer. His other clinical interests include mediastinal and chest wall tumors, tracheal disorders, thoracic outlet syndrome, and benign esophageal diseases.&nbsp;<quillbot-extension-portal></quillbot-extension-portal>

Research Focus

Dr. Vimolratana&rsquo;s research focuses on improving patient outcomes after complex lung and esophageal surgery. He has shared his findings through publications in peer-reviewed journals and abstracts at national meetings.&nbsp;<quillbot-extension-portal></quillbot-extension-portal>

Elsevier Profile

EMR ID

163553

Biography

<p>Marc Vimolratana, MD, MS, is Assistant Professor, Cardiothoracic and Vascular Surgery at Montefiore Einstein. Dr. Vimolratana is a general thoracic surgeon with a clinical focus on thoracic surgical oncology, including minimally invasive surgery for lung and esophageal cancer. His other clinical interests include mediastinal and chest wall tumors, tracheal disorders, thoracic outlet syndrome, and benign esophageal diseases. Dr. Vimolratana takes a patient-centered approach to patient care and is committed to using minimally invasive techniques, including VATS and robotic surgery, whenever possible to minimize surgical trauma and pain for patients.</p><p>Dr. Vimolratana studied chemistry at Yale, earning a Bachelor of Science and Master of Science in 2006. He attended medical school at the University of California, San Francisco, earning a Doctor of Medicine in 2014. After many years in California, he moved to New York for postdoctoral training at NewYork-Presbyterian Hospital/Weill Cornell Medical Center, where he completed a residency in general surgery in 2019, serving as chief resident in his final year. Dr. Vimolratana continued at NewYork-Presbyterian Hospital for fellowship training in cardiothoracic surgery prior to joining the faculty at Montefiore Einstein in 2021.</p><p>Dr. Vimolratana&rsquo;s research focuses on improving patient outcomes after complex lung and esophageal surgery. He has shared his findings through publications in peer-reviewed journals and abstracts at national meetings.</p><p>Dr. Vimolratana is certified by the American Board of Thoracic Surgery and the American Board of Surgery. He is a member of several professional organizations, including the American College of Surgeons, the Society of Thoracic Surgeons and the European Society of Thoracic Surgeons. He has been honored with numerous awards for academic excellence and clinical care.</p>

Is Open Scheduling

Off

Ellen D. Teplitz

https://assets.montefioreeinstein.org/profiles/images/2882-teplitz.jpg

First Name

Ellen

Last Name

Teplitz

NPI

1174683742

Faculty ID

2882

CMO Specialties

Clinical Terms

Employment Status

Per Diem

Patient Type

Adult

Department

Gender

Female

Email

Phone

Titles

Locations

Education and Trainings

Research Profile

Clinical Profile

CHAM Provider

Off

Professional Title

EMR ID

3602

Is Open Scheduling

Off

Brendon M. Stiles

https://assets.montefioreeinstein.org/profiles/images/Stiles_Brendon_MD_2x.jpg

First Name

Brendon

Last Name

Stiles

NPI

1013176387

Faculty ID

16884

CMO Specialties

Clinical Terms

Employment Status

Full Time

Patient Type

Adult

Department

Gender

Male

Email

Phone

Titles

Locations

Education and Trainings

Professional Interests

<p class="MsoNoSpacing">Brendon Stiles, MD, is Professor and Chief, Thoracic Surgery and Surgical Oncology, Department of Cardiothoracic &amp; Vascular Surgery at Montefiore-Einstein.&nbsp; Dr. Stiles is also the Associate Director for Surgical Services in the Montefiore-Einstein Cancer Center. Dr. Stiles&rsquo; clinical focus is on the treatment of lung and esophageal cancer and on neoadjuvant immunotherapy. Taking a patient-first philosophy, Dr. Stiles provides world-class personalized care, using minimally invasive, organ-sparing techniques and targeting surgical therapy to the specific needs of the patient and his or her individual tumor.</p>
<p class="MsoNoSpacing">Dr. Stiles is also heavily involved with translational and basic research.&nbsp; Translationally, Dr. Stiles is interested in neoadjuvant immunotherapy and in predicting and augmenting response to immunotherapy.&nbsp; &nbsp;In the laboratory, he has been funded by the AATS, TSF, the Lung Cancer Research Foundation, the DOD CDMRP Lung Cancer Research Program, and the Mark Foundation.&nbsp;</p>
<p class="MsoNoSpacing">Dr. Stiles' laboratory currently investigates the protein ART1, an extracellular mono-ADP-ribosyltransferase.&nbsp; Recently, Dr. Stiles and his team discovered that ART1 may play an important role in one mechanism of resistance in lung cancers. ART1 mono-ADP-ribosylates the P2X7 receptor (P2X7R) on immune cells, which ultimately causes NAD-induced cell death (NICD) in T cells, macrophages, and dendritic cells. They found ART1 to be highly expressed in multiple human non-small cell lung cancer cell lines and in the majority of human lung adenocarcinomas they sampled.<span style="mso-spacerun: yes;">&nbsp; </span>ART1 expression allows cancers to blunt the immune response against them. Indeed, they found that inhibiting ART1 with a therapeutic monoclonal antibody in mouse models of lung cancer caused a dramatic reduction of tumor burden and an enrichment of immune cells in the tumor.</p>
<p class="MsoNoSpacing"><span style="font-size: 12pt;">Current efforts are underway to better understand regulation of ART1 expression, to identify more targets of extracellular mono-ADP-ribosylation, and to refine pre-clincal models to test their therapeutic antibody targeting ART1.</span></p>
<p class="MsoNoSpacing">&nbsp;</p>
<p class="MsoNoSpacing">&nbsp;</p>

Research Areas

Specialties

Expert Tags

Areas of Expertise

Expert Summary

<p>Dr. Stiles’ clinical focus is on the treatment of lung and esophageal cancer and on neoadjuvant immunotherapy. Taking a patient-first philosophy, Dr. Stiles provides world-class personalized care, using minimally invasive, organ-sparing techniques and targeting surgical therapy to the specific needs of the patient and his or her individual tumor.
</p>

Research Profile

Clinical Profile

CHAM Provider

Off

Professional Title

Clinical Focus

Dr. Stiles&rsquo; clinical focus is on the treatment of lung and esophageal cancer and unusual thoracic cancers including metastatic tumors and those invading the heart. He also has a clinical interest in treating benign chest and upper gastrointestinal diseases.&nbsp;<quillbot-extension-portal></quillbot-extension-portal>

Research Focus

Dr. Stiles is actively involved in both clinical and translational research, particularly focusing on lung cancer. His clinical research concentrates on the management of early stage or screen detected lung cancer and on novel multidisciplinary treatment strategies for patients with lung cancer.&nbsp; In the laboratory, he investigates a protein called ART1 and its role in protecting cancer cells from the immune system. He has developed a novel drug targeting ART1 with a goal of advancing it to clinical use. He has co-authored numerous manuscripts on the management of early stage or screen-detected lung cancer, guidelines for the management of early stage lung cancer, papers regarding neoadjuvant immunotherapy for lung cancer patients and a comprehensive review on the tumor microenvironment in lung cancer.<quillbot-extension-portal></quillbot-extension-portal>

Elsevier Profile

Selected Publications

<p style="margin-right: 0in; margin-left: 0in; font-size: 12pt; font-family: 'Times New Roman', serif;"><span style="font-family: Arial, sans-serif;">Wennerberg, Erik et al, Expression of the mono-ADP-ribosyltransferase ART1 by tumor cells mediates immune resistance in non-small cell lung cancer.&nbsp;&nbsp;<em>Science Translational Medicine.&nbsp;</em>2022 Mar 16;14(636):eabe8195.&nbsp;&nbsp;</span><u style="font-family: Verdana, Arial, Helvetica, sans-serif; font-size: 14px;"><span style="font-size: 11.0pt; font-family: 'Calibri',sans-serif; mso-fareast-font-family: Calibri; mso-fareast-theme-font: minor-latin; color: #0563c1; mso-ansi-language: EN-US; mso-fareast-language: EN-US; mso-bidi-language: AR-SA;"><a href="https://nam04.safelinks.protection.outlook.com/?url=https%3A%2F%2Fwww.s…;
<p style="margin-right: 0in; margin-left: 0in; font-size: 12pt; font-family: 'Times New Roman', serif;"><span style="font-family: Arial, sans-serif; color: #222222;">Altorki, Nasser K., et al. "The lung microenvironment: an important regulator of tumour growth and metastasis."&nbsp;</span><em style="font-size: 12pt;"><span style="font-family: Arial, sans-serif;">Nature Reviews Cancer</span></em><span style="font-size: 12pt;">&nbsp;19.1 (2019): 9-31.</span></p>
<p style="margin-right: 0in; margin-left: 0in; font-size: 12pt; font-family: 'Times New Roman', serif;"><span style="font-family: Arial, sans-serif; color: #222222;">Yao, Zhan, et al. "TGF-&beta; IL-6 axis mediates selective and adaptive mechanisms of resistance to molecular targeted therapy in lung cancer."&nbsp;</span><em><span style="font-family: Arial, sans-serif;">Proceedings of the National Academy of Sciences</span></em>&nbsp;107.35 (2010): 15535-15540.</p>
<p style="margin-right: 0in; margin-left: 0in; font-size: 12pt; font-family: 'Times New Roman', serif;"><span style="font-family: Arial, sans-serif; color: #222222;">Gao, Dingcheng, et al. "Myeloid progenitor cells in the premetastatic lung promote metastases by inducing mesenchymal to epithelial transition."&nbsp;</span><em><span style="font-family: Arial, sans-serif;">Cancer research</span></em>&nbsp;72.6 (2012): 1384-1394.</p>
<p style="margin-right: 0in; margin-left: 0in; font-size: 12pt; font-family: 'Times New Roman', serif;"><span style="font-family: Arial, sans-serif; color: #222222;">Altorki, Nasser K., et al. "Neoadjuvant durvalumab with or without stereotactic body radiotherapy in patients with early-stage non-small-cell lung cancer: A single-centre, randomised phase 2 trial."&nbsp;</span><em><span style="font-family: Arial, sans-serif;">The Lancet Oncology</span></em>&nbsp;22.6 (2021): 824-835.</p>
<p style="margin-right: 0in; margin-left: 0in; font-size: 12pt; font-family: 'Times New Roman', serif;"><span style="font-family: Arial, sans-serif; color: #222222;">Wennerberg, Erik, et al. "Expression of ART1, an extracellular mono ADP-ribosylase, promotes lung cancer growth and dissemination by limiting tumor infiltration of P2X7R+ CD8+ T cells and CD103+ dendritic cells."&nbsp;</span><em><span style="font-family: Arial, sans-serif;">JOURNAL FOR IMMUNOTHERAPY OF CANCER</span></em>. Vol. 7. CAMPUS, 4 CRINAN ST, LONDON N1 9XW, ENGLAND: BMC, 2019.</p>
<p style="margin-right: 0in; margin-left: 0in; font-size: 12pt; font-family: 'Times New Roman', serif;"><span style="font-family: Arial, sans-serif; color: #222222;">Chen, Chuang, et al. "ART1, an extracellular ADP-ribosyltransferase, is over-expressed in non-small cell lung cancer and facilitates cancer cell survival by immune-mediated mechanisms."&nbsp;</span><em><span style="font-family: Arial, sans-serif;">Journal of Thoracic Oncology</span></em>&nbsp;11.2 (2016): S44.</p>
<p style="margin-right: 0in; margin-left: 0in; font-size: 12pt; font-family: 'Times New Roman', serif;"><span style="font-family: Arial, sans-serif; color: #222222;">https://scholar.google.com/citations?user=fR4OkgkAAAAJ&amp;hl=en&amp;oi…;

EMR ID

82842

Biography

<p>Brendon Stiles, MD, is Professor and Chief, Thoracic Surgery and Surgical Oncology, Department of Cardiothoracic &amp; Vascular Surgery at Montefiore Einstein, and the Associate Director for Surgical Services in the Montefiore Einstein Cancer Center. Dr. Stiles&rsquo; clinical focus is on the treatment of lung and esophageal cancer and unusual thoracic cancers including metastatic tumors and those invading the heart. He also has a clinical interest in treating benign chest and upper gastrointestinal diseases. Taking a patient-first philosophy, Dr. Stiles provides world-class personalized care, using minimally invasive, organ-sparing techniques and targeting surgical therapy to the specific needs of the patient and his or her individual tumor.</p><p>&ldquo;The recruitment of&nbsp;Dr. Stiles elevates the treatment of lung cancer to a historic level,&rdquo; said Robert E. Michler, MD, Surgeon-in-Chief and Chairman and Professor, Department of Surgery and Department of Cardiothoracic &amp; Vascular Surgery at Montefiore-Einstein. &ldquo;Every thoracic surgical therapy available anywhere in the world will now be offered by Dr. Stiles at Montefiore-Einstein.&rdquo;</p><p>After earning his Bachelor of Arts in 1994 at the University of Virginia, Dr. Stiles continued at UVA, earning his Doctor of Medicine in 1999.&nbsp; He conducted his training in general surgery at the University of Virginia Health System. From 2001 to 2003, Dr. Stiles served as a surgical research fellow at Memorial Sloan-Kettering Cancer Center before returning to the University of Virginia Health System to complete his surgical residency. Dr. Stiles completed a cardiothoracic surgery residency at NewYork-Presbyterian Hospital-Weill Cornell and Memorial Sloan-Kettering Cancer Center in 2008. Dr. Stiles joined the faculty at NewYork-Presbyterian Hospital-Weill Cornell before being recruited by Dr. Michler to Montefiore-Einstein in 2021.</p><p>Dr. Stiles is actively involved in both clinical and translational research, particularly focusing on lung cancer. His clinical research concentrates on the management of early stage or screen detected lung cancer and on novel multidisciplinary treatment strategies for patients with lung cancer.&nbsp; In the laboratory, he investigates a protein called ART1 and its role in protecting cancer cells from the immune system. He has developed a novel drug targeting ART1 with a goal of advancing it to clinical use. He has co-authored numerous manuscripts on the management of early stage or screen-detected lung cancer, guidelines for the management of early stage lung cancer, papers regarding neoadjuvant immunotherapy for lung cancer patients and a comprehensive review on the tumor microenvironment in lung cancer. In addition to publications in peer-reviewed journals, he has also given several invited national and international talks on his research and on the clinical management of lung and esophageal cancer.</p><p>Dr. Stiles is highly active in the lung cancer care community, having lost his own father to lung cancer in 2005. He is committed to raising money for lung cancer research, serving as chair of the Lung Cancer Research Foundation since 2017. He is also an invited member of the National Lung Cancer Roundtable and on the Lung-RADS Steering Committee for lung cancer screening with the American College of Radiology.&nbsp; Dr. Stiles is a member of several professional organizations including the American Association for Thoracic Surgery, the Society of Thoracic Surgeons, the American Society of Clinical Oncology, the European Society of Thoracic Surgeons and the International Association for the Study of Lung Cancer.</p>

Is Open Scheduling

Off

Beth N. McLellan

https://assets.montefioreeinstein.org/profiles/images/physphoto/McLellan_Beth_MD_LC_420x504.jpg

First Name

Beth

Last Name

McLellan

NPI

1356512412

Faculty ID

14084

CMO Specialties

Clinical Terms

Employment Status

Full Time

Patient Type

Adult

Department

Gender

Female

Email

Phone

Titles

Locations

Education and Trainings

Professional Interests

<p class="MsoNormal" style="mso-margin-top-alt: auto; mso-margin-bottom-alt: auto; line-height: normal;"><span style="font-size: 10.5pt; font-family: Verdana, sans-serif;">Beth McLellan graduated with honors from Northwestern University and attended medical school at Wayne State University where she graduated with Alpha Omega Alpha honors. She completed an internship in Internal Medicine at Loyola University Health System and her Dermatology residency at Henry Ford Health System in Detroit where she also served as Chief Resident. She currently is a Professor in the Department of Medicine (Dermatology) and has served as Chief of the Division of Dermatology since 2020.</span></p>
<p class="MsoNormal" style="mso-margin-top-alt: auto; mso-margin-bottom-alt: auto; line-height: normal;"><span style="font-size: 10.5pt; font-family: Verdana, sans-serif;">Dr. McLellan specializes in complex medical Dermatology and has a special interest in Supportive Oncodermatology - the treatment of dermatologic diseases in cancer patients. She works closely with oncologists to prevent and treat skin, hair, and nail-related side effects due to cancer therapies and is committed to improving the lives of cancer patients.</span></p>
<p class="MsoNormal" style="mso-margin-top-alt: auto; mso-margin-bottom-alt: auto; line-height: normal;"><span style="font-size: 10.5pt; font-family: Verdana, sans-serif;">Dr. McLellan leads research examining radiation dermatitis and was the first to describe baseline bacterial colonization as a risk factor for severe radiation dermatitis as well as successful use of bacterial decolonization for prevention of radiation dermatitis. She has published numerous articles and textbook chapters related to Supportive Oncodermatology and is regularly invited to speak at Dermatology and Oncology conferences for physicians and patients including the annual meeting of the American Academy of Dermatology, ASCO, and Gilda's Club.</span></p>
<p class="MsoNormal" style="margin-bottom: 0in; line-height: normal;"><span style="font-size: 10.5pt; font-family: Verdana, sans-serif;">Playing an active role in the Dermatology Residency, Dr. McLellan is the director of resident research and regularly lectures residents and medical students. She has served as a mentor to many residents and students and directs a year-long Oncodermatology research fellowship for medical students taking a year off for research.&nbsp; Interested medical students can learn more about the fellowship here: https://www.einsteinmed.edu/departments/medicine/divisions/dermatology/…;
<div>&nbsp;</div>
<div>&nbsp;</div>
<div>&nbsp;</div>
<p>&nbsp;</p>

Research Areas

Research Profile

Clinical Profile

CHAM Provider

Off

Professional Title

Clinical Focus

Dr. McLellan specializes in complex medical dermatology and has a special interest in supportive oncodermatology - the treatment of dermatologic diseases in cancer patients. She works closely with oncologists to prevent and treat skin, hair and nail-related side effects due to cancer therapies and is committed to improving the lives of cancer patients.

Research Focus

Dr. McLellan leads research examining radiation dermatitis and was the first to describe baseline bacterial colonization as a risk factor for severe radiation dermatitis

Elsevier Profile

Selected Publications

<p><a href="https://www.ncbi.nlm.nih.gov/sites/myncbi/1-KCbcoWaApUyh/bibliography/5…;

EMR ID

5777

Biography

<p>Beth N. McLellan, MD, is Chief, Dermatology, Director, Supportive Oncodermatology and Professor, Dermatology at Montefiore Einstein. She specializes in complex medical dermatology and has a special interest in supportive oncodermatology - the treatment of dermatologic diseases in cancer patients. She works closely with oncologists to prevent and treat skin, hair and nail-related side effects due to cancer therapies and is committed to improving the lives of cancer patients.</p><p>After earning her Doctor of Medicine at Wayne State University, Dr. McLellan completed an internship in internal medicine at Loyola University Health System and her dermatology residency at Henry Ford Health System where she also served as chief resident and initiated a supportive oncodermatology clinic. Dr. McLellan received additional oncodermatology training at Memorial Sloan Kettering Cancer Center and at the Institut Gustave Roussy in Paris, France.</p><p>Dr. McLellan leads research examining radiation dermatitis and was the first to describe baseline bacterial colonization as a risk factor for severe radiation dermatitis. Playing an active role in the Montefiore Einstein Dermatology Residency, Dr. McLellan is the Director of Resident Research and regularly lectures residents and medical students at both dermatology and oncology meetings. She has served as a mentor to many residents and students and directs a year long oncodermatology research fellowship for medical students taking a year off for research. Dr. McLellan has published numerous articles and textbook chapters related to supportive oncodermatology and is regularly invited to speak at dermatology and oncology conferences for physicians and patients, including the annual meeting of the American Academy of Dermatology, American Society of Clinical Oncology and Gilda's Club.</p><p>As part of her commitment to treating the whole patient, Dr. McLellan founded the New York Vitiligo Support Group. She has received awards from the Dermatology Foundation.</p>

Is Open Scheduling

On

Ranon E. Mann

https://documentapi-fargate-documentbucket-15qi4tpdvnhlz.s3.amazonaws.com/218/c72bf490-4533-11ef-aaf9-f7685684de7b.jpg

First Name

Ranon

Last Name

Mann

NPI

1730279530

Faculty ID

5362

CMO Specialties

Clinical Terms

Employment Status

Full Time

Patient Type

Adult

Department

Gender

Male

Email

Phone

Titles

Locations

Education and Trainings

Research Profile

Clinical Profile

CHAM Provider

Off

Professional Title

Clinical Focus

As Program Director my clinical focus is patient care and resident education. My interests surround<br />complex medical dermatology.

Research Focus

Research focus on skin disorders affecting patients who are HIV positive.

Elsevier Profile

EMR ID

4051

Is Open Scheduling

On

Tobi B. Klar

https://documentapi-fargate-documentbucket-15qi4tpdvnhlz.s3.amazonaws.com/218/bbff55b0-470e-11ec-a9e7-9bd94149ce2f.jpg

First Name

Tobi

Last Name

Klar

NPI

1609934264

Faculty ID

5357

CMO Specialties

Clinical Terms

Employment Status

part-time

Patient Type

Adult

Department

Gender

Female

Email

Phone

Titles

Locations

Education and Trainings

Research Profile

Clinical Profile

CHAM Provider

Off

Professional Title

Clinical Focus

<span style="font-family:Calibri, sans-serif;font-size:16px;">Dr. Klar&rsquo;s clinical expertise includes general dermatological procedures, as well as more complex procedures such as the treatment of psoriasis and inflammatory dermatoses with phototherapy, topical therapy and biologic therapy.</span>

Research Focus

<span style="font-family:Calibri, sans-serif;font-size:16px;">Dr. Klar&rsquo;s research interests are in treatment options for acne, psoriasis and eczema.</span>

EMR ID

46138

Biography

<p><span style="font-size:12.0pt;font-family:'Calibri',sans-serif;">Tobi Klar, MD, is an attending physician and Assistant Professor at Montefiore-Einstein. Dr. Klar&rsquo;s clinical expertise includes general dermatological procedures, as well as more complex procedures such as the treatment of psoriasis and inflammatory dermatoses with phototherapy, topical therapy and biologic therapy. Dr. Klar also treats cancers of the skin including melanoma, basal cell carcinoma and squamous cell carcinoma.<span>&nbsp; </span>She has advanced training and extensive experience treating adults and children for general dermatological conditions, including rashes, acne, rosacea and eczema. She also performs skin cancer screenings and treats premalignant and malignant conditions.</span></p> <p><span style="font-size:12.0pt;font-family:'Calibri',sans-serif;">After earning her Doctor of Medicine at the State University of New York Downstate in 1981, Dr. Klar continued at the institution for her postdoctoral training, completing her Internal Medicine Internship in 1982, her Internal Medicine Residency in 1983 and her Dermatology Residency in 1986.</span></p> <p><span style="font-size:12.0pt;font-family:'Calibri',sans-serif;">Dr. Klar&rsquo;s research interests are in treatment options for acne, psoriasis and eczema. </span></p> <p><span style="font-size:12.0pt;font-family:'Calibri',sans-serif;">Dr. Klar is board certified and is a member of several professional associations including the Society for Clinical Vascular Surgery, the Society of Vascular Ultrasound and the Peripheral Vascular Surgery Society.</span></p>

Is Open Scheduling

On

Holly E. Kanavy

https://documentapi-fargate-documentbucket-15qi4tpdvnhlz.s3.amazonaws.com/218/30558870-44a1-11ef-8a01-f9048202cb80.jpg

First Name

Holly

Last Name

Kanavy

NPI

1386965408

Faculty ID

14352

CMO Specialties

Clinical Terms

Employment Status

Full Time

Patient Type

Adult

Department

Gender

Female

Email

Phone

Titles

Locations

Education and Trainings

Professional Interests

<p>Dr. Holly Kanavy completed a B.S. in Biochemistry with Departmental Honors in Neuroscience at Stony Brook University and a medical degree at New York College of Osteopathic Medicine, where she received the A.T. Still Memorial Scholarship Award and was a member of the Psi Sigma Alpha National Osteopathic Scholastic Honor Society. Following an internship at North Shore/LIJ Plainview Hospital, Dr. Kanavy completed two fellowships, one in Melanoma Translational Research at NYU Langone Medical Center, and another in Dermatopharmacology at University Hospitals Case Medical Center in Cleveland, Ohio. She then completed a dermatology residency at Saint Barnabas Hospital in the Bronx, serving as chief resident.</p>
<p>Dr. Kanavy is currently active in the study of dermoscopic patterns of acral nevi. She has received several awards and grants, including the A.P. Ublrich Research Award for her work in the study of acral nevi and the Bayer Healthcare Writing Grant Competition for her study of skin cancer chemoprevention.&nbsp; She has contributed to numerous dermatology journals and textbooks, including <em>Archives in Dermatology, Photodermatology, Photoimmunology &amp; Photomedicine, </em><em> Journal of the American Osteopathic College of Dermatology, </em>and<em> Cancer of the Skin.</em></p>
<p><!-- [if gte mso 9]><xml>
<o:OfficeDocumentSettings>
<o:AllowPNG/>
</o:OfficeDocumentSettings>
</xml><![endif]--></p>

Research Profile

Clinical Profile

CHAM Provider

Off

Professional Title

Elsevier Profile

EMR ID

69621

Is Open Scheduling

On

Pamela J. Jakubowicz

https://assets.montefioreeinstein.org/profiles/images/physphoto/Jakubowicz_Pamela_Jasmine_S_MD_11115820.jpg

First Name

Pamela

Last Name

Jakubowicz

NPI

1598861510

Faculty ID

10714

CMO Specialties

Clinical Terms

Employment Status

Full Time

Patient Type

Adult

Department

Gender

Female

Email

Phone

Titles

Locations

Education and Trainings

Research Profile

Clinical Profile

CHAM Provider

Off

Professional Title

Elsevier Profile

EMR ID

4451

Is Open Scheduling

On